Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ444444,50,00
KB495496-2,08
PKN48,348,35-3,55
Msft-1,24
Nokia3,4513,5215-2,38
IBM-1,73
Daimler AG45,7445,755-1,98
PFE-0,52
19.09.2020 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2020 21:59:37
Vertex Pharma (VRTX.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
265,43 -2,23 -6,04 1 475 680
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.09.2020
Popis společnosti
Obecné informace
Název společnostiVertex Pharmaceuticals Incorporated
TickerVRTX
Kmenové akcie:Ordinary Shares
RICVRTX.O
ISINUS92532F1003
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 3 000
Akcie v oběhu k 23.07.2020 260 467 334
Počet akcionářů k 31.12.2019 1 102
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice50 Northern Ave
MěstoBOSTON
PSČ02210-1862
ZeměUnited States
Kontatní osobaMichael Partridge
Funkce kontaktní osobyVice President - Investor Relations
Telefon16 173 416 393

Business Summary: Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Vertex Pharmaceuticals Incorporated revenues increased 69% to $3.04B. Net income increased from $536.1M to $1.44B. Revenues reflect United States segment increase of 79% to $2.4B, Europe` segment increase of 48% to $515.1M. Net income benefited from Derivatives - Hedging - Gain/Loss increase from $2.1M to $16.2M (income), Interest expense decrease of 6% to $28M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 20.09.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardJeffrey Leiden6301.04.2020
President, Chief Executive Officer, DirectorReshma Kewalramani4601.04.202001.04.2018
Chief Financial Officer, Executive Vice PresidentCharles Wagner4810.04.201910.04.2019
Executive Vice President, Chief Legal and Administrative OfficerMichael Parini4401.01.2017
Executive Vice President - Global Research, Chief Scientific OfficerDavid Altshuler54
Executive Vice President, Chief Commercial OfficerStuart Arbuckle5404.09.201204.09.2012
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical OfficerCarmen Bozic-01.04.202001.04.2020
Executive Vice President, Commercial OperationsGerald Bruce-17.09.201917.09.2019
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEOAmit Sachdev51
Senior Vice President, ControllerPaul Silva5210.04.201929.09.2008